Literature DB >> 18242888

Evaluation of indirect fluorescent antibody test (IFAT) for the diagnosis and screening of lumpy skin disease using Bayesian method.

G Gari1, F Biteau-Coroller, C LeGoff, P Caufour, F Roger.   

Abstract

The performance of indirect fluorescence antibody test (IFAT) for serological diagnosis and screening of lumpy skin disease (LSD) was evaluated using methods without gold standard. Virus neutralization test (VNT) was used as the second test and the study sites were selected from two different geographical places in Ethiopia to get different disease prevalence. The analysis of conditional dependent Bayesian model for the accuracy of IFAT showed that sensitivity, specificity, prevalence of the population Pi(1) and the population Pi(2) were 0.92 (0.89-0.95), 0.88 (0.85-0.91), 0.28 (0.25-0.32) and 0.06 (0.048-0.075), respectively. The posterior inferences obtained for VNT sensitivity, specificity and conditional correlation between the tests for sensitivity (rhoD) and specificity (rhoDc) were 0.78 (0.74-0.83), 0.97 (0.95-0.99), 0.052 (-0.03-0.15) and 0.019 (-0.01-0.06), respectively. The interval estimation of conditional correlation for both sensitivity and specificity clusters around zero and thus conditional dependence between the two tests was not significant. Although accuracy measure would not be the only basis for test selection, the result of our study demonstrated that IFAT has a reasonable high accuracy to be used for the diagnosis and sero-surveillance analysis of LSD in the target population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18242888     DOI: 10.1016/j.vetmic.2007.12.005

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  8 in total

Review 1.  Living with transboundary animal diseases (TADs).

Authors:  Paul B Rossiter; Najib Al Hammadi
Journal:  Trop Anim Health Prod       Date:  2008-12-03       Impact factor: 1.559

2.  Seroprevalence and Associated Risk Factors of Lumpy Skin Disease of Cattle in Selected Districts of Afar Region, Ethiopia.

Authors:  Teshager Dubie; Fentaw Hussen Abegaz; Beyene Dereje; Wossene Negash; Muhammed Hamid
Journal:  Vet Med (Auckl)       Date:  2022-08-16

3.  Sensitive and Specific Detection of Lumpy Skin Disease Virus in Cattle by CRISPR-Cas12a Fluorescent Assay Coupled with Recombinase Polymerase Amplification.

Authors:  Chuanwen Jiang; Dagang Tao; Yuanchen Geng; Hao Yang; Bingrong Xu; Yingyu Chen; Changmin Hu; Huanchun Chen; Shengsong Xie; Aizhen Guo
Journal:  Genes (Basel)       Date:  2022-04-22       Impact factor: 4.141

4.  An Immunoperoxidase Monolayer Assay (IPMA) for the detection of lumpy skin disease antibodies.

Authors:  Andy Haegeman; Ilse De Leeuw; Laurent Mostin; Willem Van Campe; Laetitia Aerts; Maria Vastag; Kris De Clercq
Journal:  J Virol Methods       Date:  2019-12-16       Impact factor: 2.014

5.  Bayesian Estimation of Sensitivity and Specificity of Rose Bengal, Complement Fixation, and Indirect ELISA Tests for the Diagnosis of Bovine Brucellosis in Ethiopia.

Authors:  T Getachew; G Getachew; G Sintayehu; M Getenet; A Fasil
Journal:  Vet Med Int       Date:  2016-08-09

6.  Sero-prevalence of lumpy skin disease in selected districts of West Wollega zone, Ethiopia.

Authors:  Zelalem Abera; Hailu Degefu; Getachew Gari; Menbere Kidane
Journal:  BMC Vet Res       Date:  2015-06-17       Impact factor: 2.741

7.  Humoral immune response to repeated lumpy skin disease virus vaccination and performance of serological tests.

Authors:  Milovan Milovanović; Klaas Dietze; Vesna Milićević; Sonja Radojičić; Miroslav Valčić; Tom Moritz; Bernd Hoffmann
Journal:  BMC Vet Res       Date:  2019-03-06       Impact factor: 2.741

8.  Suitability of individual and bulk milk samples to investigate the humoral immune response to lumpy skin disease vaccination by ELISA.

Authors:  Milovan Milovanović; Vesna Milićević; Sonja Radojičić; Miroslav Valčić; Bernd Hoffmann; Klaas Dietze
Journal:  Virol J       Date:  2020-03-05       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.